AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
oxybuprocaine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| local anaesthetics | 3016 | 99-43-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,KIT,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 | 63 | |||
| kinase-selectivity-class | AXL,BRAF,CAMK2D,DYRK1B,MAPK7,NUAK1,PDK4,PRKCD,SIK2,SIK3,STK33,TEK,TTK | 13 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 9, 2020 | FDA | BAUSCH |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic anterior segment syndrome | 168.42 | 119.91 | 21 | 92 | 2229 | 90626105 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic anterior segment syndrome | 177.05 | 89.31 | 24 | 165 | 3430 | 110585680 |
| Aqueous fibrin | 123.68 | 89.31 | 13 | 176 | 201 | 110588909 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D04AB03 | DERMATOLOGICALS ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. Anesthetics for topical use |
| ATC | S01HA02 | SENSORY ORGANS OPHTHALMOLOGICALS LOCAL ANESTHETICS Local anesthetics |
| MeSH PA | D000777 | Anesthetics |
| MeSH PA | D000779 | Anesthetics, Local |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
| CHEBI has role | CHEBI:36333 | local anaesthetic |
| CHEBI has role | CHEBI:48425 | topical anaesthetic |
| CHEBI has role | CHEBI:88188 | drug allergen |
Related Drugs by ATC class:
D04AB Anesthetics for topical use 6 drugs
S01HA Local anesthetics 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Topical local anesthetic to eye | indication | 231346001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.8 | Basic |
| pKa2 | 2.87 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.4%;0.3% | FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE | BAUSCH LOMB IRELAND | N211039 | March 9, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 10293047 | Nov. 15, 2037 | OCULAR EXAMINATION, INTRAOCULAR PRESSURE MEASUREMENT, OR REMOVAL OF FOREIGN BODIES OR SUTURES, IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC |
| 0.4%;0.3% | FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE | BAUSCH LOMB IRELAND | N211039 | March 9, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 10632197 | Nov. 15, 2037 | OCULAR EXAMINATION, INTRAOCULAR PRESSURE MEASUREMENT, OR REMOVAL OF FOREIGN BODIES OR SUTURES, IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC |
| 0.4%;0.3% | FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE | BAUSCH LOMB IRELAND | N211039 | March 9, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 10842872 | Nov. 15, 2037 | PROCEDURES IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC. |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium channel protein type 10 subunit alpha | Ion channel | BLOCKER | DRUGBANK | CHEMBL | |||||
| Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | BLOCKER | IC50 | 5.54 | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019627 | VUID |
| N0000179047 | NUI |
| D08319 | KEGG_DRUG |
| 5987-82-6 | SECONDARY_CAS_RN |
| 4018751 | VANDF |
| 4019627 | VANDF |
| CHEBI:309594 | CHEBI |
| CHEMBL1200 | ChEMBL_ID |
| CHEMBL1200654 | ChEMBL_ID |
| C005298 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7123 | IUPHAR_LIGAND_ID |
| DB00892 | DRUGBANK_ID |
| 18889 | RXNORM |
| 4253 | MMSL |
| 001355 | NDDF |
| 004569 | NDDF |
| 370315001 | SNOMEDCT_US |
| 387063004 | SNOMEDCT_US |
| 52140009 | SNOMEDCT_US |
| C0053114 | UMLSCUI |
| 4633 | PUBCHEM_CID |
| 275 | INN_ID |
| AXQ0JYM303 | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Fluorescein Sodium and Benoxinate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 24208-734 | SOLUTION/ DROPS | 4.40 mg | OPHTHALMIC | NDA | 21 sections |
| ALTAFLUOR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 59390-218 | SOLUTION | 4 mg | OPHTHALMIC | NDA | 21 sections |
| Fluorescein Sodium and Benoxinate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 82260-734 | SOLUTION/ DROPS | 4.40 mg | OPHTHALMIC | NDA authorized generic | 21 sections |